Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01698905
Title Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

chronic myeloid leukemia

Therapies

Nilotinib

Age Groups: adult
Covered Countries USA | FRA | ESP | DEU | CAN | BEL


No variant requirements are available.